Quizartinib Boosts AML Survival, Regardless of SCT Quizartinib Boosts AML Survival, Regardless of SCT
Adding quizartinib to standard induction chemotherapy significantly improves overall survival in patients with newly diagnosed acute myeloid leukemia regardless of prior stem cell transplantation.MDedge News
Source: Medscape Transplantation Headlines - Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplant Surgery | Transplants